Overview

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the protocol, is to determine whether lanreotide 30 mg is effective in the treatment of patients with digestive fistulae.
Phase:
Phase 3
Details
Lead Sponsor:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin